Earnings digests and industry comparisons for Japan's biggest listed companies.
15 reports(page 2 of 2)
Takeda reported that the US Food and Drug Administration has accepted its new drug application for the psoriasis treatment zasocitinib. The approval target date is set for the first quarter of 2027 following the priority review status.
Daiichi Sankyo has secured a complete victory in its long-running legal dispute with NTK, as the Tokyo District Court dismissed all of the opponent's claims on September 10, 2026.
Otsuka Holdings (4578) on the 28th raised its first-half FY2026 net profit forecast by 68% to ¥215 billion, marking a record high. The upgrade was fueled by brisk sales of mainstay drugs, a weaker yen, and restrained R&D expenses.
